Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Three of the strong evidence associations involve RASSF1 methylation on bladder cancer risk (OR = 18.46; 95% CI: 12.69-26.85; I<sup>2</sup> = 0%), MGMT methylation on NSCLC (OR = 4.25; 95% CI: 2.83-6.38; I<sup>2</sup> = 22.4%) and RARB methylation on prostate cancer (OR = 6.87; 95% CI: 4.68-10.08; I<sup>2</sup> = 0%).
|
31202904 |
2019 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
All biopsy cores from the negative index biopsy were profiled for the epigenetic biomarkers GSTP1, APC, and RASSF1 using ConfirmMDx for Prostate Cancer (MDxHealth, Irvine, CA).
|
29660369 |
2019 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The androgen-receptor gene (AR-CAG) repeat length and the percentage of promoter methylation (PPM) of genes glutathione-S-transferase P1 (GSTP1) and Ras association domain family 1 isoform A (RASSF1A) improve PCa detection.
|
29571584 |
2018 |
Prostate carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
The probes specifically hybridized with the methylated targets only in the MSP-DB, which allowed detecting GSTP1 and RASSF1A methylation in 23 of 50 and 14 of 50 patients with prostate cancer and in 2 of 17 and 4 of 17 patients with benign prostate hyperplasia.
|
25577235 |
2015 |
Prostate carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
In a univariate model RASSF1 methylation and the total number of methylated genes in prostate cancer tissue were predictive of time to biochemical recurrence (p = 0.019 and 0.043, respectively).
|
24980613 |
2014 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our meta-analyses identified strong associations of four aberrantly methylated genes (GSTP1, RASSF1, p16, and RARB) with PCa.
|
25053593 |
2014 |
Prostate carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
In conclusion, this meta-analysis suggested that RASSF1A promoter methylation was significantly associated with an increased risk for PCa; furthermore, the RASSF1A methylation status in tissue rather than urine was positively correlated with GS, serum PSA level, and tumor stage, which can be utilized for the early detection and prognosis prediction of PCa.
|
24353088 |
2014 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Methylation of PITX2, HOXD3, RASSF1 and TDRD1 predicts biochemical recurrence in high-risk prostate cancer.
|
24938434 |
2014 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hypomethylation of BNIP3 (31.25 ± 16.19 vs. 45.70 ± 2.42 %, p < 0.0001), hypermethylation of Ec-SOD (71.4 ± 6.75 vs. 10.0 ± 3.78 %, p < 0.0001) and RASSF1 (76.25 ± 12.53 vs. 30.0 ± 8.82 %, p = 0.0077) was observed in prostate cancer.
|
23979608 |
2013 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Focal hypermethylation occurs at CpG islands in the promoters of certain genes including GSTP1, RARβ2, and RASSF1A with both age and cancer, while global hypomethylation is seen in prostate cancer and known to occur in the colon and other organs.
|
23999928 |
2013 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A multiplex quantitative methylation specific polymerase chain reaction assay determining the methylation status of GSTP1, APC and RASSF1 was strongly associated with repeat biopsy outcome up to 30 months after initial negative biopsy in men with suspicion of prostate cancer.
|
22999998 |
2013 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The DNA methyltransferase (DNMT) family of enzymes are known to be involved in the epigenetic silencing of gene expression, including RASSF1A, and are often overexpressed in prostate cancer.
|
24001151 |
2013 |
Prostate carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
The odds ratio (OR) of RASSF1A methylation in PCa case, compared to controls, was 14.73 with 95% CI = 7.58-28.61.
|
24073258 |
2013 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Biomarkers like GSTP1, APC and RASSF1 have demonstrated involvement with prostate cancer, with the latter two genes playing prominent roles in the field effect.
|
22672250 |
2012 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Association of tissue promoter methylation levels of APC, TGFβ2, HOXD3 and RASSF1A with prostate cancer progression.
|
21207416 |
2011 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our fluorescent lead compound up-regulated RASSF1A in vitro, potently inhibited human prostate cancer cell proliferation, and fluoresced at a visible wavelength, allowing for the observation of intracellular distribution.
|
20184324 |
2010 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Comparison of the methylation level for the matched benign and prostate cancer tissues from individual patients with prostate cancer showed significantly higher methylation in the prostate cancer tissue samples for RARbeta2 (P < 0.001), RASSF1A (P = 0.005), GSTP1 (P < 0.001), NKX2-5 (P = 0.003), ESR1 (P = 0.016), and CLSTN1 (P = 0.01).
|
17606710 |
2007 |
Prostate carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
This is the first report suggesting that reduced histone acetylation or H3K4me2 methylation and increased dimethyl-H3-K9 methylation play a critical role in the maintenance of promoter DNA methylation-associated RASSF1A gene silencing in prostate cancer.
|
17473182 |
2007 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Several recent reports suggest that suppression of RASSF1A is associated with the advanced grade and stage of prostate cancer and many other cancers.
|
17698033 |
2007 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These observations suggest that methylation of the RASSF1A gene is present in both pre-malignant and benign epithelia and suggests quantitation is required for it to be an effective marker of early prostate cancer.
|
17342751 |
2007 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
GSTP1 Promotor hypermethylation was detectable in 75% of plasma samples obtained from patients with newly diagnosed prostate cancer and in 36.8% of patients under therapy, whereas 26% and 14% of the breast cancer patients tested were positive for RASSF1A and ATM methylation, respectively.
|
17108217 |
2006 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Methylation of GSTP1, RARB, CD44, ECAD and RASSF1A, but not of EDNRB was detected at a statistically higher frequency in prostate cancer than in the benign prostatic hypertrophy specimens.
|
15289848 |
2004 |
Prostate carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
In conclusion, our data suggest that epigenetic inactivation of RASSF1A by methylation is a very common event in prostate cancer and might be involved in the progression of the disease.
|
12360410 |
2002 |
Prostate carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
However, no silencing of RASSF1A was found in four other prostate carcinoma cell lines, which were adapted for cell culture after transformation with human papillomaviral DNA.
|
12067994 |
2002 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In this study, we analyzed the expression and mutation status of three RASSF1 isoforms (-A, -B, and -C) in 55 primary bladder carcinomas and 10 bladder and prostate cancer cell lines.
|
11559536 |
2001 |